 SOUTH SAN FRANCISCO, Calif., March 11, 2021 PRNewswire -- Rigel Pharmaceuticals, Inc. Nasdaq: RIGL today announced the completion of patient enrollment in a multi-center Phase 2 clinical trial to evaluate the safety of fostamatinib, Rigels oral spleen tyrosine kinase SYK inhibitor, for the treatment of hospitalized COVID-19 patients. 